Rationale and design of the HOVON 170 DLBCL-ANTICIPATE trial: preventing anthracycline-induced cardiac dysfunction with dexrazoxane by Marijke Linschoten, Jesse Geels, Erik van Werkhoven, Heleen Visser-Wisselaar, Martine E. D. Chamuleau, Arco J. Teske, Lourens Robbers, Simone Oerlemans, Heleen Crommelin, Marleen Breems-de Ridder, Astrid Schut, Folkert W. Asselbergs, Anna van Rhenen, on behalf of the HOVON 170 DLBCL – ANTICIPATE consortium

Get full text

Regional disparities in the use of intensive chemotherapy for AML in the Netherlands: does it influence survival? by Hester F Lingsma, David van Klaveren, Arjan A van de Loosdrecht, Anna van Rhenen, Otto Visser, Valery E P P Lemmens, Nikki van Leeuwen, Gerwin Huls, Z L Rana Kaplan, Eduardus F M Posthuma, Danielle van Lammeren-Venema, Tjeerd J F Snijders, Catharina H M J van Elssen, Peter A von dem Borne, Nicole M A Blijlevens, Jan J Cornelissen, Marc H G P Raaijmakers, Avinash G Dinmohamed

Get full text

A randomised, open-label trial to assess the optimal treatment strategy in early diffuse cutaneous systemic sclerosis: the UPSIDE study protocol by Vanessa Smith, Ellen De Langhe, Jacob M van Laar, Alexandre E Voskuyl, Madelon C Vonk, Roger Hesselstrand, Ulrich A Walker, Dirk M Wuttge, Reinhard E Voll, Arjan A van de Loosdrecht, Julia Spierings, Joerg Henes, Anna van Rhenen, Paco MW Welsing, Anne CA Marijnissen, Nicoletta Del Papa, Daan Dierickx, Karina R Gheorghe, Tessa Kerre, Per Ljungman, Erik WAF Marijt, Miro Mayer, Marc Schmalzing, Roland Schroers, Jeska K de Vries-Bouwstra

Get full text